Spero Therapeutics, Inc. (SPRO)

NASDAQ: SPRO · IEX Real-Time Price · USD
11.23
-0.17 (-1.49%)
Jan 28, 2022 1:38 PM EST - Market open
Market Cap362.99M
Revenue (ttm)17.42M
Net Income (ttm)-79.10M
Shares Out32.32M
EPS (ttm)-2.67
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume119,729
Open11.36
Previous Close11.40
Day's Range10.92 - 11.60
52-Week Range10.86 - 22.24
Beta1.53
AnalystsStrong Buy
Price Target41.50 (+269.5%)
Earnings Daten/a

About SPRO

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment ...

IndustryBiotechnology
IPO DateNov 2, 2017
CEOAnkit Mahadevia
Employees89
Stock ExchangeNASDAQ
Ticker SymbolSPRO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for SPRO stock is "Strong Buy." The 12-month stock price forecast is 41.50, which is an increase of 269.55% from the latest price.

Price Target
$41.50
(269.55% upside)
Analyst Consensus: Strong Buy

News

Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administer...

New award option exercised by BARDA brings the total potential funding from its existing contract with Spero up to $59.7 million New award option exercised by BARDA brings the total potential funding fr...

1 week ago - GlobeNewsWire

FDA Lifts Clinical Hold On Spero Therapeutics' Lung Infection Program

The FDA has lifted the clinical hold on Spero Therapeutics Inc's (NASDAQ: SPRO) Phase 2 trial of SPR720 for nontuberculous mycobacterial (NTM) disease. The SPR720 program was placed on a clinical hold b...

3 weeks ago - Benzinga

Spero (SPRO) Application for UTI Drug Gets Priority Review

Spero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review.

3 weeks ago - Zacks Investment Research

Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 2 ...

3 weeks ago - GlobeNewsWire

Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Tre...

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022 The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022

3 weeks ago - GlobeNewsWire

Spero Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...

2 months ago - GlobeNewsWire

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Tops Revenue Estimates

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 0.00% and 2.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Spero Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on Wednesday, November ...

CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...

2 months ago - GlobeNewsWire

Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Spero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinar...

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...

3 months ago - GlobeNewsWire

Spero Therapeutics Appoints Kathleen Tregoning to its Board of Directors

Ms. Tregoning brings more than two decades of experience in biotechnology and public policy to Spero's Board Ms. Tregoning brings more than two decades of experience in biotechnology and public policy t...

3 months ago - GlobeNewsWire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...

3 months ago - GlobeNewsWire

Spero Therapeutics Inks Revenue Interest Financing Agreement With HealthCare Royalty Partners

Spero Therapeutics Inc (NASDAQ: SPRO) has entered into a revenue interest financing agreement with HealthCare Royalty Partners for up to $125 million.  Spero will use the proceeds to prepare for the ant...

Other symbols:HCRX
3 months ago - Benzinga

Spero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners® ...

Investment expected to extend Spero Therapeutics' cash runway into 2H 2023 Investment expected to extend Spero Therapeutics' cash runway into 2H 2023

3 months ago - GlobeNewsWire

Spero Therapeutics to Present Data at IDWeek 2021

CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializi...

4 months ago - GlobeNewsWire

Spero Therapeutics to Present at Three Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializin...

4 months ago - GlobeNewsWire

Here's Why Momentum Investors Will Love Spero Therapeutics, Inc. (SPRO)

Does Spero Therapeutics, Inc. (SPRO) have what it takes to be a top stock pick for momentum investors? Let's find out.

4 months ago - Zacks Investment Research

Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 18.18% and 101.88%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Recap: Spero Therapeutics Q2 Earnings

Shares of Spero Therapeutics (NASDAQ:SPRO) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 25.88% over the past year to ($0.63), whic...

5 months ago - Benzinga

Spero Therapeutics Announces Second Quarter 2021 Operating Results and Provides Business Update

Tebipenem HBr on track for NDA submission in the fourth quarter of 2021

5 months ago - GlobeNewsWire

Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Spero Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results on Thursday, August 5,...

CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializin...

5 months ago - GlobeNewsWire

Spero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...

6 months ago - GlobeNewsWire

DuPont De Nemours, Inc Among Today's Trending Stocks

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified DuPont De Nemours, Inc among others.

Other symbols:DDACIAPITSN
6 months ago - Forbes

Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in e...

SHANGHAI, July 5, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products for patients in Grea...

Other symbols:PFE
6 months ago - PRNewsWire